Institutional Ownership
Cns Pharmaceuticals Inc
CUSIP 18978H508COMCNSPQ1 2026
13D / 13G Filings
2
Schedule 13D/13G on record
Beneficial Filers
1
Distinct reporting persons
Largest Stake
7.9%
Max % of class reported
Institutional Holders
11
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
2 filings · latest Feb 13, 2026
Top Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Stonepine Capital Management, LLC | 61.0K | $145.8K |
| 2 | Ikarian Capital, LLC | 45.8K | $110.0K |
| 3 | Geode Capital Management, LLC | 23.2K | $55.7K |
| 4 | Boothbay Fund Management, LLC | 13.5K | $32.3K |
| 5 | Tower Research Capital LLC (Trc) | 1.3K | $3.1K |
| 6 | Ubs Group AG | 729 | $1.7K |
| 7 | Barrett & Company, Inc. | 8 | $19 |
| 8 | Mai Capital Management | 3 | $8 |
| 9 | Danske Bank A/S | 1 | $2 |
| 10 | Citigroup Inc | 1 | $2 |